4.4 Article

Mass balance, metabolic disposition, and pharmacokinetics of a novel selective inhibitor of PI3Kδ [14C] SHC014748M in healthy Chinese subjects following oral administration

Related references

Note: Only part of the references are listed.
Article Pharmacology & Pharmacy

Duvelisib for the treatment of chronic lymphocytic leukemia

Anna Maria Frustaci et al.

EXPERT OPINION ON PHARMACOTHERAPY (2020)

Article Oncology

Copanlisib in the treatment of non-Hodgkin lymphoma

Mayur Narkhede et al.

FUTURE ONCOLOGY (2020)

Article Engineering, Biomedical

Adaptable antibody Nanoworms designed for non-Hodgkin lymphoma

Changrim Lee et al.

BIOMATERIALS (2020)

Article Oncology

Global patterns and trends in the incidence of non-Hodgkin lymphoma

Adalberto Miranda-Filho et al.

CANCER CAUSES & CONTROL (2019)

Article Immunology

PIK3IP1/TrIP restricts activation of T cells through inhibition of PI3K/Akt

Uzodinma U. Uche et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2018)

Review Oncology

Hodgkin Lymphoma: A Review and Update on Recent Progress

Satish Shanbhag et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2018)

Article Pharmacology & Pharmacy

Idelalisib: First Global Approval

Anthony Markham

DRUGS (2014)

Article Oncology

Selenium and sulindac are synergistic to inhibit intestinal tumorigenesis in Apc/p21 mice

Xiuli Bi et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)

Article Pharmacology & Pharmacy

The application of sample pooling methods for determining AUC, AUMC and mean residence times in pharmacokinetic studies

BWY Cheung et al.

FUNDAMENTAL & CLINICAL PHARMACOLOGY (2005)